Denovo Therapeutics

First patient dosed in unique biomarker guided Ph III study of enzastaurin + R-CHOP in high-risk diffuse large B-cell lymphoma (DLBCL)
CP Wire
Wed, 04/4/18 - 09:53 am
biomarkers
enzastaurin
Denovo Therapeutics
DLBCL
R-CHOP